Long-term prophylaxis in bipolar disorder

CNS Drugs

Volumn 20, Issue 4, 2006, Pages 303-310

  Taylor, Matthew J ^a   Goodwin, Guy M ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; LAMOTRIGINE; LITHIUM; OLANZAPINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROIC ACID;

BIPOLAR I DISORDER; CLINICAL TRIAL; CONGENITAL MALFORMATION; DRUG EFFICACY; DRUG INDUCED DISEASE; EBSTEIN ANOMALY; FETAL HYDANTOIN SYNDROME; HEALTH EDUCATION; HUMAN; KIDNEY FUNCTION; LIVER FUNCTION; LONG TERM CARE; MANIA; META ANALYSIS; MORTALITY; NEURAL TUBE DEFECT; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROPHYLAXIS; RECURRENT DISEASE; REVIEW; RISK FACTOR; SUICIDE ATTEMPT; SYMPTOM; SYSTEMATIC REVIEW;

AGE FACTORS; ANTIMANIC AGENTS; BIPOLAR DISORDER; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LACTATION; LONG-TERM CARE; MALE; PRACTICE GUIDELINES; PREGNANCY; PREVENTIVE MEDICINE; SEX FACTORS;

EID: 33645704212     PISSN: 11727047     EISSN: 11727047     Source Type: Journal    
DOI: 10.2165/00023210-200620040-00004     Document Type: Review

References (44)

1. Murray CJ, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 1997; 349 (9063): 1436-42
2. Malhi GS, Mitchell PB, Berk M, et al. Mood stabilizers: a labile label. Acta Psychiatr Scand Suppl 2005; (426): 5-6
3. Goodwin GM, Young AH. The British Association for Psychopharmacology guidelines for treatment of bipolar disorder: a summary. J Psychopharmacol 2003; 17 (4 Suppl.): 3-6
4. Grunze H, Kasper S, Goodwin G, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders, part III: maintenance treatment. World J Biol Psychiatry 2004; 5 (3): 120-35
5. American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder. 2nd ed. Washington, DC: American Psychiatric Association, 2002
6. Yatham LN, Kennedy SH, Donovan C, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies. Bipolar Disord 2005; 7 Suppl. 3: 5-69
7. Kessing LV, Hansen MG, Andersen PK, et al. The predictive effect of episodes on the risk of recurrence in depressive and bipolar disorders: a life-long perspective. Acta Psychiatr Scand 2004; 109 (5): 339-44
8. Fagiolini A, Frank E, Scott JA, et al. Metabolic syndrome in bipolar disorder: findings from the Bipolar Disorder Center for Pennsylvanians. Bipolar Disord 2005; 7 (5): 424-30
9. Goodwin GM. Recurrence of mania after lithium withdrawal: implications for the use of lithium in the treatment of bipolar affective disorder. Br J Psychiatry 1994; 164 (2): 149-52
10. Geddes JR, Burgess S, Hawton K, et al. Long-term lithium therapy for bipolar disorder: systematic review and meta-analysis of randomized controlled trials. Am J Psychiatry 2004; 161 (2): 217-22
11. Cipriani A, Wilder H, Hawton K, et al. Lithium in the prevention of suicidal behaviour and all-cause mortality in patients with mood disorders: a systematic review of randomised trials. Am J Psychiatry 2005; 162 (10): 1805-19
12. Tondo L, Hennen J, Baldessarini RJ. Lower suicide risk with long-term lithium treatment in major affective illness: a meta-analysis. Acta Psychiatr Scand 2001; 104 (3): 163-72
13. Bowden CL, Calabrese JR, McElroy SL, et al. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder: Divalproex Maintenance Study Group. Arch Gen Psychiatry 2000; 57 (5): 481-9
14. Macritchie KA, Geddes JR, Scott J, et al. Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorder. Cochrane Database Syst Rev 2001; (3): CD003196
15. Tohen M, Ketter TA, Zarate CA, et al. Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study. Am J Psychiatry 2003; 160 (7): 1263-71
16. Goodwin GM, Bowden CL, Calabrese JR, et al. A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder. J Clin Psychiatry 2004; 65 (3): 432-41
17. Tohen M, Greil W, Calabrese JR, et al. Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial. Am J Psychiatry 2005; 162 (7): 1281-90
18. Tohen M, Calabrese JR, Sachs GS, et al. Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine. Am J Psychiatry 2006; 163 (2): 247-56
19. Tohen M, Chengappa KN, Suppes T, et al. Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser vs mood stabiliser alone. Br J Psychiatry 2004; 184: 337-45
20. Davis JM, Janicak PG, Hogan DM. Mood stabilizers in the prevention of recurrent affective disorders: a meta-analysis. Acta Psychiatr Scand 1999; 100 (6): 406-17
21. Greil W, Kleindienst N. The comparative prophylactic efficacy of lithium and carbamazepine in patients with bipolar I disorder. Int Clin Psychopharmacol 1999; 14 (5): 277-81
22. Hartong EG, Moleman P, Hoogduin CA, et al. Prophylactic efficacy of lithium versus carbamazepine in treatment-naive bipolar patients. J Clin Psychiatry 2003; 64 (2): 144-51
23. Ghaemi SN, Lenox MS, Baldessarini RJ. Effectiveness and safety of long-term antidepressant treatment in bipolar disorder. J Clin Psychiatry 2001; 62 (7): 565-9
24. Altshuler L, Suppes T, Black D, et al. Impact of antidepressant discontinuation after acute bipolar depression remission on rates of depressive relapse at 1-year follow-up. Am J Psychiatry 2003; 160 (7): 1252-62
25. Soldani F, Ghaemi SN, Tondo L, et al. Relapse after antidepressant discontinuation. Am J Psychiatry 2004; 161 (7): 1312-3 [author reply 1313]
26. McQuade RD, Sanchez R, Marcus R. Aripiprazole for relapse prevention in bipolar disorder: a 26-week placebo controlled study [abstract] Int J Neuropsychopharmacol 2004; 7 (Suppl 1): 161
27. Denicoff KD, Smith-Jackson EE, Disney ER, et al. Comparative prophylactic efficacy of lithium, carbamazepine, and the combination in bipolar disorder. J Clin Psychiatry 1997; 58 (11): 470-8
28. Geddes J, Goodwin G. Bipolar disorder: clinical uncertainty, evidence-based medicine and large-scale randomised trials. Br J Psychiatry 2001; 178 Suppl. 41: S191-4
29. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994
30. Salloum IM, Thase ME. Impact of substance abuse on the course and treatment of bipolar disorder. Bipolar Disord 2000; 2 (3 Pt 2): 269-80
31. Scott J, Gutierrez MJ. The current status of psychological treatments in bipolar disorders: a systematic review of relapse prevention. Bipolar Disorders 2004; 6 (6): 498-503
32. Suppes T, Baldessarini RJ, Faedda GL, et al. Discontinuation of maintenance treatment in bipolar disorder: risks and implications. Harv Rev Psychiatry 1993; 1 (3): 131-44
33. Sproule BA, Hardy BG, Shulman KI. Differential pharmacokinetics of lithium in elderly patients. Drugs Aging 2000; 16 (3): 165-77
34. Brockington IF. Motherhood and mental health. Oxford: Oxford University Press, 1996
35. Rosa FW. Spina bifida in infants of women treated with carbamazepine during pregnancy. N Engl J Med 1991; 324 (10): 674-7
36. Kaneko S, Battino D, Andermann E, et al. Congenital malformations due to antiepileptic drugs. Epilepsy Res 1999; 33 (2-3): 145-58
37. Hanson JW, Smith DW. The fetal hydantoin syndrome. J Pediatr 1975; 87 (2): 285-90
38. Samren EB, van Duijn CM, Christiaens GC, et al. Antiepileptic drug regimens and major congenital abnormalities in the offspring. Ann Neurol 1999; 46 (5): 739-46
39. Cohen LS, Friedman JM, Jefferson JW, et al. A reevaluation of risk of in utero exposure to lithium [published erratum appears in JAMA 1994 May 18; 271 (19): 1485]. JAMA 1994; 271 (2): 146-50
40. Brockington IF. Puerperal psychosis. In: Brockington IF, editor. Motherhood and mental health. Oxford: Oxford University Press, 1996: 200-84
41. Jones I, Craddock N. Bipolar disorder and childbirth: the importance of recognising risk. Br J Psychiatry 2005; 186: 453-4
42. Yonkers KA, Wisner KL, Stowe Z, et al. Management of bipolar disorder during pregnancy and the postpartum period. Am J Psychiatry 2004; 161 (4): 608-20
43. Yoshida K, Smith B, Kumar R. Psychotropic drugs in mothers' milk: a comprehensive review of assay methods, pharmacokinetics and of safety of breast-feeding. J Psychopharmacol 1999; 13 (1): 64-80
44. Chaudron LH, Jefferson JW. Mood stabilizers during breastfeeding: a review. J Clin Psychiatry 2000; 61 (2): 79-90